- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
BASi Shares Improved Strategy for Enhanced Bioequivalence
Bioanalytical Systems announced a new strategy for the potential enhancement their in vitro and in vivo bioequivalence capabilities.
Bioanalytical Systems (NASDAQ:BASI) announced a new strategy for the potential enhancement their in vitro and in vivo bioequivalence capabilities.
As quoted in the press release:
Over the next several months, BASi will hire additional Principal Investigators and Research Analysts to support the company’s Bioanalytical and Pharm Analysis labs, and provide expanded cross training for current staff. Additionally, capital investments are being made for new and upgraded automated dissolution apparatus equipment for the company’s Pharm Analysis labs. These upgrades will not only provide improved data, a commitment at the heart of BASi’s pledge to its clients, but will increase capacity as well. The company will also increase its already extensive library of validated analytical methods applicable to in vivo bioequivalence studies.
BASi has extensive experience in performing in vitro bioequivalence studies as described in regulatory guidances and demonstrated by successful regulatory audits of the company’s work. BASi is actively engaged in developing new methods to be utilized for recent, new guidances. Some of the products requiring in vitro bioequivalence testing include sevelamer carbonate and hydrochloride, lanthanum carbonate, cholestyramine powder, colesevelam hydrochloride, calcium carbonate and colestipol.
Click here to read the full press release.
Source: www.accesswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.